A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Clinical trial NCT03901963 · COMPLETED
Trial details
- NCT number
- NCT03901963
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-26
- Primary completion
- 2024-04-04
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.